Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LNTH
stocks logo

LNTH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
369.75M
-5.46%
1.189
-25.21%
355.34M
-4.68%
1.210
-20.92%
367.56M
-2.77%
1.290
-17.83%
Estimates Revision
The market is revising Upward the revenue expectations for Lantheus Holdings, Inc. (LNTH) for FY2025, with the revenue forecasts being adjusted by 1.39% over the past three months. During the same period, the stock price has changed by 13.00%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.39%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.16%
In Past 3 Month
Stock Price
Go Up
up Image
+13.00%
In Past 3 Month
Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 76.83 USD with a low forecast of 61.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 76.83 USD with a low forecast of 61.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 61.870
sliders
Low
61.00
Averages
76.83
High
99.00
Current: 61.870
sliders
Low
61.00
Averages
76.83
High
99.00
B. Riley
Buy
downgrade
$109 -> $84
2025-09-16
Reason
B. Riley
Price Target
$109 -> $84
2025-09-16
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Lantheus to $84 from $109 and keeps a Buy rating on the shares. The firm views the near-term risk for Lantheus as whether Pylarify further loses market share and that Pylarify will be surpassed by Illuccix/Gozellix before 2nd-generation Pylarify receives pass-through status in the second half of 2026, the analyst tells investors in a research note. The firm waits for a stabilization of the stock price and better visibility into the long-term growth prospects in the next 6-12 months.
TD Cowen
Buy
downgrade
$95 -> $80
2025-09-15
Reason
TD Cowen
Price Target
$95 -> $80
2025-09-15
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Lantheus to $80 from $95 and keeps a Buy rating on the shares. The firm lowered our Pylarify pricing assumptions for 2025-2026, which should begin to recover in 2027 upon potential approval of the new formulation. They also increased their OpEx estimates, resulting in decreased 2025 EPS that is consistent with the company's guidance.
Truist
Richard Newitter
Buy
to
Hold
downgrade
$111 -> $63
2025-08-11
Reason
Truist
Richard Newitter
Price Target
$111 -> $63
2025-08-11
downgrade
Buy
to
Hold
Reason
Truist analyst Richard Newitter downgraded Lantheus to Hold from Buy with a price target of $63, down from $111.
Truist
Buy
to
Hold
downgrade
$111 -> $63
2025-08-11
Reason
Truist
Price Target
$111 -> $63
2025-08-11
downgrade
Buy
to
Hold
Reason
As previously reported, Truist downgraded Lantheus to Hold from Buy with a price target of $63, down from $111. While the firm "appreciates" the stock's selloff reflects "a lot of Pylarify uncertainty already," it thinks the multiple is going to be linked to Pylarify trends and it sees year-over-year and quarter-over-quarter deceleration as now on tap for "at least" another two quarters. While the firm still sees "underappreciated value" to the long-term pipeline, it believes shares could "mark time" for the next six months or so until there is more certainty that the second half is the bottom for Pylarify after two quarters of misses and lowering linked to it.
Citizens JMP
Outperform
maintain
$112 -> $73
2025-08-07
Reason
Citizens JMP
Price Target
$112 -> $73
2025-08-07
maintain
Outperform
Reason
Citizens JMP lowered the firm's price target on Lantheus to $73 from $112 and keeps an Outperform rating on the shares following the Q2 report. The firm attributes the Q2 miss and guidance cut to the impact of competitor Blue Earth's pricing strategy taking a bigger toll on Pylarify's business. Despite this, domestic volumes still grew 2% year-over-year, the analyst tells investors in a research note. Citizens remains encouraged about Lantheus' royalty opportunities including Flyrcado and Pylclari.
Mizuho
Outperform -> NULL
downgrade
$120 -> $70
2025-08-07
Reason
Mizuho
Price Target
$120 -> $70
2025-08-07
downgrade
Outperform -> NULL
Reason
Mizuho lowered the firm's price target on Lantheus to $70 from $120 and keeps an Outperform rating on the shares post the Q2 report. The firm says Pylarify competitive headwinds create uncertainty for the company's outlook. It sees Pylarify pressures extending into next year.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lantheus Holdings Inc (LNTH.O) is 12.26, compared to its 5-year average forward P/E of 19.77. For a more detailed relative valuation and DCF analysis to assess Lantheus Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
19.77
Current PE
12.26
Overvalued PE
32.47
Undervalued PE
7.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.46
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
14.70
Undervalued EV/EBITDA
6.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.79
Current PS
0.00
Overvalued PS
4.71
Undervalued PS
2.87
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 5211.12% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 2127.26% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 5211.12% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LNTH News & Events

Events Timeline

(ET)
2025-11-06
07:59:19
Lantheus CEO Markison to Retire; Heino Named Interim Successor
select
2025-11-06
07:34:21
Lantheus revises FY25 adjusted EPS forecast to a range of $5.50-$5.65, down from $5.50-$5.70
select
2025-11-06
07:32:48
Lantheus announces Q3 adjusted EPS of $1.27, matching consensus expectations.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
Lantheus Presents New Florbetaben F18 Data at CTAD 2025 Conference on December 3
  • New Data Presentation: Lantheus Holdings will present new florbetaben F18 data at the 2025 Clinical Trials on Alzheimer's Disease conference, scheduled for December 1-4 in San Diego, CA. This presentation aims to provide clinicians with deeper insights into disease detection and treatment, potentially influencing future therapeutic decisions.
  • Poster Presentation Details: On December 3, the company will showcase findings on florbetaben's binding to amyloid plaques, particularly its interaction with antibodies lecanemab and donanemab. These results may offer critical clinical insights for amyloid beta-targeted therapies.
  • Safety Information: The use of Neuraceq carries risks for image interpretation errors, which may affect the estimation of amyloid beta neuritic plaque density. The company emphasizes the need to interpret images independently of clinical information to enhance accuracy and ensure safe clinical applications.
  • Company Background: Lantheus is a leading radiopharmaceutical-focused company with nearly 70 years of experience, dedicated to advancing the discovery, treatment, and monitoring of diseases through science. Headquartered in Massachusetts, it has offices in multiple countries, showcasing its extensive global operations.
[object Object]
Preview
7.0
11-13Globenewswire
Bragar Eagel & Squire Launches Investigation into Officers and Directors of Quantum, Unicycive, Fly-E, and Lantheus for Long-Term Stockholders; Invites Investors to Reach Out to the Firm

  • Quantum Corporation Investigation: Bragar Eagel & Squire is investigating Quantum Corporation's officers and directors due to a class action lawsuit alleging improper revenue recognition and misleading statements regarding the company's financial health, leading to investor damages.

  • Unicycive Therapeutics Investigation: The law firm is also looking into Unicycive Therapeutics following a class action complaint that claims the company misrepresented its readiness to meet FDA manufacturing compliance, resulting in significant stock price drops after the truth was revealed.

  • Fly-E Group Investigation: An investigation is underway for Fly-E Group's executives after a class action lawsuit accused them of providing misleading information about the company's revenue growth and safety issues related to lithium batteries, which negatively impacted sales.

  • Lantheus Holdings Investigation: Bragar Eagel & Squire is examining Lantheus Holdings due to allegations of false statements regarding the competitive position of its product Pylarify, which may have misled investors about the company's pricing strategy and growth potential.

[object Object]
Preview
4.0
11-11Benzinga
Truist Securities Maintains Hold Rating on Lantheus Holdings, Reduces Price Target to $61

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Traders utilize Benzinga Pro's tools and intelligence to improve their chances of success in the stock market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lantheus Holdings Inc (LNTH) stock price today?

The current price of LNTH is 61.87 USD — it has increased 3.51 % in the last trading day.

arrow icon

What is Lantheus Holdings Inc (LNTH)'s business?

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.

arrow icon

What is the price predicton of LNTH Stock?

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 76.83 USD with a low forecast of 61.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lantheus Holdings Inc (LNTH)'s revenue for the last quarter?

Lantheus Holdings Inc revenue for the last quarter amounts to 384.01M USD, increased 1.39 % YoY.

arrow icon

What is Lantheus Holdings Inc (LNTH)'s earnings per share (EPS) for the last quarter?

Lantheus Holdings Inc. EPS for the last quarter amounts to 0.41 USD, decreased -77.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lantheus Holdings Inc (LNTH)'s fundamentals?

The market is revising Upward the revenue expectations for Lantheus Holdings, Inc. (LNTH) for FY2025, with the revenue forecasts being adjusted by 1.39% over the past three months. During the same period, the stock price has changed by 13.00%.
arrow icon

How many employees does Lantheus Holdings Inc (LNTH). have?

Lantheus Holdings Inc (LNTH) has 808 emplpoyees as of December 05 2025.

arrow icon

What is Lantheus Holdings Inc (LNTH) market cap?

Today LNTH has the market capitalization of 3.88B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free